Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma

Arnaud Bourdina Department of Respiratory Diseases, Université de Montpellier, CHU Montpellier, PhyMedExp, INSERM, CNRS, Montpellier, FranceCorrespondence[email protected]
View further author information

, MD, PhD,

Dominick Shawb Division of Respiratory Medicine, University of Nottingham, Nottingham, UKView further author information

, MD,

Andrew Menzies-Gowc Department of Respiratory Medicine, Royal Brompton Hospital, London, UKView further author information

, MD, PhD,

J. Mark FitzGeraldd Centre for Heart and Lung Health, The Lung Centre Vancouver General Hospital, UBC Institute for Heart and Lung Health, Vancouver, CanadaView further author information

, MD,

Eugene R. Bleeckere Divisions of Pharmacogenomics and Genetics, Genomics and Precision Medicine, University of Arizona College of Medicine, Tucson, AZ, USAView further author information

, MD,

William W. Bussef Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USAView further author information

, MD,

Gary T. Fergusong Pulmonary Medicine, Internal Medicine, Critical Care Medicine, Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USAView further author information

, MD,

Laura Brooksh Research and Development, AstraZeneca, Gaithersburg, MD, USAView further author information

, MSc,

Peter Barkerh Research and Development, AstraZeneca, Gaithersburg, MD, USAView further author information

, PhD,

Esther Garcia Gili Global Medical Affairs, AstraZeneca, Barcelona, SpainView further author information

, MD &

Ubaldo J. Martinh Research and Development, AstraZeneca, Gaithersburg, MD, USAView further author information

, MD show all

Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date